Back

Microtubule Acetylation Regulates the Malignant Phenotype of Glioblastoma and is a Promising Therapeutic Target

Rosenfeld, S.;Zarco, N.;Dovas, A.;Bhattacharya, S.;Kulkarni, T.;Amini, M.;Liu, Y.;Haddock, A.;Nagaiah, N.;Mukhopadhyay, D.;Suarez-Meade, P.;Quinones-Hinojosa, A.;Miller, C.;Kamenecka, T.;Canoll, P.;Kenchappa, R.

2026-06-19 Cancer Biology
10.64898/2026.06.15.732342 bioRxiv
Show abstract

Glioblastoma (GBM) is universally lethal despite decades of research to find effective treatments. This highlights the need to identify druggable targets essential for sustaining the malignant phenotype but dispensable for normal tissue. We propose that the enzyme -tubulin acetyl transferase (ATAT1) meets these criteria. ATAT1 acetylates -tubulin at lysine 40, which increases microtubule stability and promotes microtubule-based transport. While ATAT1 knockout mice have only a very mild phenotype, ATAT1 suppression in GBM has multiple therapeutic effects by reducing tumor invasion, proliferation, and therapeutic resistance. These translate not only into improved survival with ATAT1 targeting by itself, but also into synergy when ATAT1 deletion is combined with FDA approved therapies. This study strongly supports our conclusion that ATAT1 is a promising therapeutic target in GBM.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.